___

• 1. Bozkurt, B., Coats, A.J., Tsutsui, H., Abdelhamid, C.M., Adamopoulos, S., Albert, N., Anker, S.D., Atherton, J., Böhm, M., Butler, J., Drazner, M.H., Felker, G.M., Filippatos, G., Fiuzat, M., Fonarow, G.C., Gomez-Mesa J.E., Heidenreich, P., Imamura, T., Jankowska, E.A., Januzzi, J., Khazanie, P., Kinugawa, K., Lam, C.S.P., Matsue, Y., Metra, M., Ohtani, T., Piepoli, M.F., Ponikowski, P., Rosano G.M.C., Sakata, Y., Seferovic, P., Starling, R.C., Teerlink, J.R., Vardeny, O., Yamamoto, K., Yancy, C., Zhang, J., Zieroth, S. (2021). Universal definition and classification of heart failure: A report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. European Journal of Heart Failure, 23(3), 352-380. [CrossRef]
• 2. Urbich, M., Globe, G., Pantiri, K., Heisen, M., Bennison, C., Wirtz, H.S., Di Tanna, G.L. (2020). A systematic review of medical costs associated with heart failure in the USA (2014-2020). PharmacoEconomics, 38, 1219-1236. [CrossRef]
• 3. Watanabe, K., Ohta, Y., Inoue, M., Ma, M., Wahed, M.I., Nakazawa, M., Hasegawa, G., Naito, M., Fuse, K., Ito, M., Kato, K., Hanawa, H., Kodama, M., Aizawa, Y. (2001). Bisoprolol improves survival in rats with heart failure. Journal of Cardiovascular Pharmacology, 38(1), S55-S58. [CrossRef]
• 4. Konyakhin, A.Yu. (2009). Modern pathogenetic approaches to the correction of myocardial ischemia. Abstract of the dissertation of the doctor of medical sciences, 47.
• 5. Wenningmann. N., Knapp, M., Ande, A., Vaidya, T.R., Ait-Oudhia, S. (2019). Insights into doxorubicin-induced cardiotoxicity: Molecular mechanisms, preventive strategies, and early monitoring. Molecular Pharmacology, 96(2), 219-232. [CrossRef]
• 6. Bien, S., Riad, A., Ritter, C.A., Gratz, M., Olshausen, F., Westermann, D., Kroemer, H.K. (2007). The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy. Cancer Research, 67(21), 10428-10435. [CrossRef]
• 7. Mazur, I., Belenichev, I., Kucherenko, L., Bukhtiyarova, N., Puzyrenko, A., Khromylova, O., Gorchakova, N. (2019). Antihypertensive and cardioprotective effects of new compound 1-(β-phenylethyl)-4-amino-1, 2, 4-triazolium bromide (Hypertril). European Journal of Pharmacology, 853, 336-344. [CrossRef]
• 8. Mazur, I.A., Belenichev, I.F., Kolesnik, Yu.M., Kucherenko, L. (2010). 1-(β-phenylethyl)-4-amino-1,2,4-thiatriazolium (MT) bromide with cardioprotective, anti-ishemic, antihypertensive, antioxidant, protein syntetic and energy-tropic action. Patent 2404974.
• 9. Chekman, I.S., Belenichev, I.F., Kucherenko, L.I., Mazur, I.A., Nagornaia, E.A., Bukhtiiarova, N.V. (2013). Parniuk NV. NO-dependent mechanisms of cardioprotective activity of mt preparation during course administration to SHR rats. Eksperimental’naia i Klinicheskaia Farmakologiia, 76(8), 24-26.
• 10. Khloponin, D.P. (2009). Analysis of possible mechanisms of pharmacological reversal of cardiac remodeling in chronic heart failure (Doctoral dissertation). Volgograd State Medical University, Volgograd.
• 11. Sidorov, A.V. (2013). Neurohumoral aspects in the implementation of prognostic effects of β-andreblockers and ACE in chronic heart failure. Doctoral dissertation. Staraya Kupavna; 412 p.
• 12. Cosentino, F., Bonetti, S., Rudolf, R., Eto, M., Werner-Felmayer, G., Volpe, M., Lüscher, T.F. (2002). Nitric-oxide-mediated relaxations in salt-induced hypertension: Effect of chronic β1-selective receptor blockade. Journal of Hypertension, 20(3), 421-428. [CrossRef]
• 13. Chen, Y., Hong, X. (2016). Effects of carvedilol reduce conjunctivitis through changes in inflammation, NGF and VEGF levels in a rat model. Experimental and Therapeutic Medicine, 11(5), 1987-1992. [CrossRef]
• 14. Kolesnik, Yu.M., Chekman, І.S., Mazur, I.A., Belenichev, I.F., Gorchakova, N.O., Nagorna, O.O. (2014). Mechanisms for the development of endothelial dysfunction and prostate endothelial protectors. Journal of the National Academy of Medical Sciences of Ukraine, 20(3), 289-299.
• 15. Maisel, A.S., Somma, S.D. (2016). Do we need another heart failure biomarker: Focus on soluble suppression on tumoregenicity 2 (sST2). European Heart Journal, 38 (30), 2325-2333. [CrossRef]
• 16. Hayakawa, H., Komada, Y., Hirayama, M., Hori, H., Ito, M., Sakurai, M. (2001). Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer. Medical and Pediatric Oncology, 37 (1), 4-9. [CrossRef]
• 17. Octavia, Y., Tocchetti, C.G., Gabrielson, K.L., Janssens, S., Crijns, H.J., Moens A.L. (2012). Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies. Journal of Molecular and Cellular Cardiology, 52(6), 1213-1225. [CrossRef]
• 18. Neilan, T.G., Blake, S.L., Ichinose, F., Raher, M.J., Buys, E.S., Jassal, D.S., Furutani, E., Perez-Sanz, T.M., Graveline, A., Janssens, S.P., Picard, M.H., Scherrer-Crosbie, M., Bloch, K.D. (2007). Disruption of nitric oxide synthase 3 protects against the cardiac injury, dysfunction, and mortality induced by doxorubicin. Circulation, 116, 506-514. [CrossRef]
• 19. Belenichev, I., Gorbachova, S., Pavlov, S., Bukhtiyarova, N., Puzyrenko, A., Brek, O. (2021). Neurochemical status of nitric oxide in the settings of the norm, ishemic event of central nervous system, and pharmacological intervention. Georgian Medical New, 315, 169-176.
• 20. Trujillo. M., Naviliat, M., Alvarez, M.N., Peluffo, G., Radi, R. (2000). Peroxynitrite biochemistry: formation, reactions and detection. Analusis, 28(6), 518-527. [CrossRef]
• 21. Gilleron, M., Marechal, X., Montaigne, D., Franczak, J., Neviere, R., Lancel, S. (2009). NADPH oxidases participate to doxorubicin-induced cardiac myocyte apoptosis. Biochemical and Biophysical Research Communications, 388(4), 727-731. [CrossRef]
• 22. Nicol, M., Sadoune, M., Polidano, E., Launay, J.M., Samuel, J.L., Azibani, F. (2021). Doxorubicin-induced and trastuzumab-induced cardiotoxicity in mice is not prevented by metoprolol ESC Heart Failure, Published online in Wiley Online Library, 8(2), 928-937. [CrossRef]
• 23. Liu, B., Li, H., Qu, H., Sun, B. (2006). Nitric oxide synthase expressions in ADR-induced cardiomyopathy in rats. BMB Reports, 39(6), 759-765. [CrossRef]
• 24. Belenichev, I.F., Bak, P.G., Abramov, A.V., Kucherenko, L.I., Bukhtiyarova, N.V., Rizhenko, V.P. (2021). ECG analysis in the simulation of chronic heart failure in rats and course administration of a new potential drug “Hypertril”. Pharmacology and Toxicology, 15(1), 20-30.
• 25. Tassigny, A., Berdeaux, A., Souktani, R., Henry, P., Ghaleh, B. (2008). The volume-sensitive chloride channel inhibitors prevent both contractile dysfunction and apoptosis induced by doxorubicin through PI3kinase, Akt and Erk 1/2. European Journal of Heart Failure, 10(1), 39-46. [CrossRef]
• 26. Ryzhov, O.A., Ryzhenko, V.P., Levich, S.V., Belenichev, I.F. (2017). Analysis of influence of quantum chemical descriptors on NO-scavenger properties among xanthine derivatives, Biological Markers and Guided Therapy, 4(1), 39-48. [CrossRef]
• 27. Youn, H.J., Kim, H.S., Jeon, M.H., Lee, J.H., Seo, Y.J., Lee, Y.J., Lee, J.H. (2005). Induction of caspase-independent apoptosis in H9c2 cardiomyocytes by adriamycin treatment. Molecular and Cellular Biochemistry, 270(1), 13-19. [CrossRef]
• 28. Bak, P.G., Belenichev, I.F., Kucherenko, L.I., Abramov, A.V., Khromylоva, O.V. (2021). Morpho-functional indicators changes of rats’ myocardium in experimental doxorubicin-induced chronic heart failure and its pharmacological modulation with new 4-amino-1,2,4-triazole derivative. Pharmacia, 68(4), 919-925. [CrossRef]